BAYN Bayer AG

By Josh Beckerman

CureVac NV reported unfavorable results in the second interim analysis of Covid-19 vaccine candidate CVnCoV, noting an "unprecedented broad diversity" of virus variants.

CureVac shares were recently down 50% after hours to $47.20.

"In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria," CureVac said. The favorable safety profile of the vaccine was confirmed.

The HERALD study, conducted by CureVac in conjunction with Bayer, enrolled about 40,000 people in 10 countries in Latin America and Europe.

In total, 134 Covid-19 cases were assessed in the interim analysis, with 124 of these sequenced to identify the variant causing the infection. The outcome confirms that only one case was attributable to the original SARS-CoV-2 virus, CureVac said.

In March, CureVac said it planned to expand and further specify the protocols of its CVnCoV trials, saying, "Rapid distribution of new virus variants in the countries where the study is conducted supports the need for further analysis specification for the anticipated case-driven interim analysis."

CureVac and GlaxoSmithKline PLC in February announced a partnership to develop a vaccine for emerging variants.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

June 16, 2021 18:11 ET (22:11 GMT)

Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024